Strong Q4 2024 results for BioMarin Pharmaceutical (BMRN): revenue up 18%, VOXZOGO's global growth leads the way. Discover 2025 strategies & growth targets.

Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to "Outperform" from "Perform," citing strong fourth-quarter results and increasing confidence in the company's long-term ...

VOXZOGO for achondroplasia experienced 56% year-over-year growth, driven by global expansion and increased penetration in younger pediatric patients. Management also revealed plans to expand ...

BioMarin总裁兼首席执行官Alexander Hardy对欢迎Walbert加入董事会表示欣喜，强调了他的运营专长和以患者为中心的服务理念。Hardy认为，Walbert的商业洞察力和专注于药物商业化的经验将极大地助力BioMarin的战略愿景。

Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...

周一，Oppenheimer分析师上调了BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )的股票评级，从"持平"上调至"优于大市"，并设定目标价为$98.00。此次上调是基于BioMarin在2024年第四季度的强劲表现，公司总收入达到$747 million，超过市场预期的$712 ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of 53 cents. The company reported sales of $747 ...

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with CAMP4 Therapeutics. The partners are using CAMP4’s regulatory RNA platform ...